Skip to main content
SpringerLink
Log in

The history of inhibitors of angiotensin converting enzyme

  • Chapter
ACE Inhibitors

Part of the book series: Milestones in Drug Therapy MDT ((MDT))

Abstract

Just over 100 years ago Felix Hoffman synthesised acetylsalicylic acid, which was marketed as Aspirin by the Bayer Company. It is now selling more than 45,000 tonnes per year. The story of the aspirin-like drugs [1] is a fascinating one, in which our discovery that they inhibit the formation of prostaglandins (PGs) [2] was a key stepping stone in its development. The enzyme involved is cyclooxygenase (COX) and we now know that there are at least two isozymes, COX-1 and COX-2. Now we have selective COX-2 inhibitors, which have the promise of being excellent anti-inflammatory drugs without the side effects on the stomach [3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Vane JR, Flower RJ, Botting RM (1990) History of aspirin and its mechanism of action. Stroke 21: 12–23

    Google Scholar 

  2. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Bio1231: 232–235

    Google Scholar 

  3. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97–120

    Article  PubMed  CAS  Google Scholar 

  4. Tiegerstedt R, Bergman P G (1898) Niere und Kreislauf. Skand Arch Physiol 8: 223–271

    Article  Google Scholar 

  5. Skeggs LTKahn JR, Shumway NP (1956) The preparation and function of the hypertensin-converting enzyme. J Exp Med 103: 295–299

    Google Scholar 

  6. Vane JR (1964) The use of isolated organs for detecting active substances in the circulating blood. Brit J Pharmacol 23: 360–373

    PubMed  CAS  Google Scholar 

  7. Vane JR (1969) The release and fate of vaso-active hormones in the circulation. Brit J Pharmacol 35: 209–242

    CAS  Google Scholar 

  8. Ng KKF, Vane JR (1967) Conversion of angiotensin Ito angiotensin II. Nature 216: 762–766

    Article  PubMed  CAS  Google Scholar 

  9. Bakhle YS, Reynard AM, Vane JR (1969) Metabolism of the Angiotensins in isolated perfused tissues. Nature 222: 956–959

    Article  PubMed  CAS  Google Scholar 

  10. Ng KKF, Vane JR (1968) Fate of angiotensin I in the circulation. Nature 218: 144–150

    Article  PubMed  CAS  Google Scholar 

  11. Yang HYT, Erdos EG, Levin Y (1971) Characterisation of a dipeptide hydrolase (kininase II: angiotensin converting enzyme). J Pharmacol Exp Ther 177: 291–298

    PubMed  CAS  Google Scholar 

  12. Ryan JW, Ryan US, Schultz DR, Whitaker C, Chung A (1975) Subcellular localization of pulmonary angiotensin-converting enzyme (kininase II). Biochem J 146: 497–499

    PubMed  CAS  Google Scholar 

  13. Ryan US (1986) Metabolic activity of endothelium: modulations of structure and function. Annu Rev Physiol 48: 263–277

    Article  PubMed  CAS  Google Scholar 

  14. Vane JR (1994) The Croonian Lecture, 1993. The endothelium: maestro of the blood circulation. Phil Trans R Soc Lond 343: 225–246

    Article  CAS  Google Scholar 

  15. Regoli D, Vane JR (1966) The continuous estimation of angiotensin formed in the circulation of the dog. J Physiol 183: 513–531

    PubMed  CAS  Google Scholar 

  16. Hodge RL, Lowe RD, Vane JR (1966) The effects of alteration of blood-volume on the concentration of circulating angiotensin In anaesthetized dogs. J Physiol 185: 613–626

    PubMed  CAS  Google Scholar 

  17. Increased angiotensin formation in response to carotid occlusion in the dog. Nature 211: 491–493

    Google Scholar 

  18. Ferreira SH (1965) A bradykinin-potentiating factor (BPF) present in the venom of Bothrops jararaca. Brit J Pharmacol 24: 163–169

    CAS  Google Scholar 

  19. Ferreira SH, Vane JR (1967) The detection and estimation of bradykinin in the circulating blood. Brit J Pharmacol 29: 367–377

    PubMed  CAS  Google Scholar 

  20. Ferreira SH, Vane JR (1967) The disappearance of bradykinin and eledoisin in the circulation and vascular beds of the cat. Brit J Pharmacol 30: 417–424

    PubMed  CAS  Google Scholar 

  21. Ferreira SH, Vane JR (1967) Half-lives of peptides and amines in the circulation. Nature 215: 1237–1240

    Article  PubMed  CAS  Google Scholar 

  22. Bakhle YS (1968) Conversion of angiotensin Ito angiotensin II by cell-free extracts of dog lung. Nature 220: 919–921

    Article  PubMed  CAS  Google Scholar 

  23. Aiken JW, Vane JR (1970) The renin-angiotensin system: inhibition of converting enzyme in isolated tissues. Nature 228: 30–34

    Article  PubMed  CAS  Google Scholar 

  24. Greene U, Camargo AC, Krieger EM, Stewart JM, Ferreira SH (1972) Inhibition of the conversion of angiotensin I to II and potentiation of bradykinin by small peptides present in Bothrops jararaca venom. Circ Res 30: 62–71

    Google Scholar 

  25. Ferreira SH, Bartelt DC, Greene U (1970) Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9: 2583–2593

    Article  PubMed  CAS  Google Scholar 

  26. Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy 0 (1971) Angiotensin-converting enzyme inhibitors from the venom of Bothrops jararaca: Isolation, elucidation of structure, and synthesis. Biochemistry 10: 4033–4039

    CAS  Google Scholar 

  27. Collier JG, Robinson BF, Vane JR (1973) Reduction of the pressor effects of angiotensin In man by a synthetic nonapeptide (BPP9a or SQ 20,881) which inhibits converting enzyme. Lancet I: 72–74

    Article  Google Scholar 

  28. Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovitch RA (1974) An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 291: 817–821

    Article  PubMed  CAS  Google Scholar 

  29. Johnson JG, Black WD, Vukovitch RA, Hatch FEJr Friedman BI, Blackwell CF, Shenouda AN, Share L, Shade RE, Acchiardo SR et al (1974) Treatment of patients with severe hypertension by inhibition of converting enzyme. Clin Sci Mol Med 48: 53s - 56s

    Google Scholar 

  30. Ondetti MA, Cushman DW (1984) Angiotensin-converting enzyme inhibition: Biochemical properties and biological actions. CRC Crit Rev Biochem 16: 381–411

    Article  PubMed  CAS  Google Scholar 

  31. Cushman DW, Ondetti MA (1991) History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 17: 589–592

    Article  PubMed  CAS  Google Scholar 

  32. Moncada S, Vane JR (1979) Prostacyclin in perspective. In: JR Vane, S Bergstrom (eds): Prostacyclin. Raven Press, New York, 5–16

    Google Scholar 

  33. Palmer MJ, Ferrige AG, Moncada S (1987) Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524–526

    Article  PubMed  CAS  Google Scholar 

  34. Ferreira SH (2000) Angiotensin Converting enzyme: History and Relevance. Semin Perinatol 24: 7–10

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Charterhouse Square, The William Harvey Research Foundation, EC1M 6BQ, London, UK

    John R. Vane

Authors
  1. John R. Vane
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Institute of Pharmacology of Sherbrooke, Medical School, Sherbrooke University, J1H-5N4, Sherbrooke, PQ, Canada

    Pedro D’Orléans-Juste  & Gérard E. Plante  & 

  2. Departments of Medicine (Nephrology), Physiology and Pharmacology, Institute of Pharmacology, University of Sherbrooke, Sherbrooke, Québec, Canada

    GĂ©rard E. Plante

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Vane, J.R. (2001). The history of inhibitors of angiotensin converting enzyme. In: D’Orléans-Juste, P., Plante, G.E. (eds) ACE Inhibitors. Milestones in Drug Therapy MDT. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-7579-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-7579-0_1

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-7581-3

  • Online ISBN: 978-3-0348-7579-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation